Introducing Kurin^®

FDA 510(k) Cleared

Typical collection sets provide skin microbes a direct line to the culture bottle, but not Kurin.

Seamlessly integrated into familiar collection sets, Kurin blood culture collection technology focuses on the contaminants originating in the patient’s own skin, which challenge hospital efforts to address false-positive blood cultures. Roughly 20% of the microbes present in skin reside deep in the dermis layer and may be drawn into blood samples.¹ Without a way to avoid these microbes, hospitals have accepted high rates of seemingly unavoidable false positives—until now.

Standing guard between the venipuncture site and the culture bottle, the Kurin Lock^™ diverts the initial blood flow that may contain microbes from deep within the skin. A clinically-relevant blood sample then bypasses the contaminants locked within the device.

Download the Kurin brochure

The problem with false-positive blood cultures

Determining whether a bloodstream infection exists is critical to the wellbeing of patients and the financial health of hospitals.

A blood culture test is the gold standard for identifying bacteremia.

Each year, millions of blood culture tests inform patient care decisions in the U.S. The majority will find no infection.¹ But, of the cultures that test positive, roughly 1/3 are false-positive results.

When blood cultures test positive—whether true or false—immediate action is taken to treat the patient with antibiotic therapy.

Roughly 20% of the microbes present in skin reside deep in the dermis layer and may be drawn into blood samples.² Without a way to avoid these microbes, hospitals have accepted high rates of seemingly unavoidable false positives—until now with the introduction of Kurin.